July 14, 2017 - Connecticut Governor Dannel Malloy has just signed into law Public Act 17-241, a bill that forbids certain contract provisions between Pharmacy Benefit Managers (PBMs) and pharmacies that limit price information that can be provided to consumers. The Act is designed to curtail what legislators termed “secret price gouging” by PBMs. PBMs, [...]
June 27, 2017 - Earlier this year, we focused one of our client alerts on a new Guidance issued by the Food and Drug Administration (FDA) concerning certain prescription requirements for compounding human drug products under section 503A of the Federal Food, Drug, and Cosmetic Act. See "FDA Issues Guidance on Prescription Requirement for Compounded [...]
Anthony Calamunci and Brian Dickerson were interviewed by RXinsider on the status of the Pharmacy industry. Each week FisherBroyles will provide access to the industry specific Q&A interview sessions hosted by RXinsider so you can learn what the newest legal and industry issues are and how to address these issues when running your pharmacy. Please [...]
Former Heritage Pharmaceuticals Execs Admit to Price Fixing Government Continues to Focus on Generic Drug Industry Since early December of 2016, we've been tracking federal price fixing charges brought against two ex-pharmaceutical executives – Jeffrey Glazer and Jason Malek – both formerly of Heritage Pharmaceuticals. On January 9, 2017, the two entered guilty pleas in [...]
FisherBroyles Partner and authority on Pharmacy Law, Brian Dickerson, talks about the increasing Federal Government targeting of pharmacy businesses in an interview on the Pharmacy Podcast Show. The FisherBroyles Pharmacy Law team has observed an increase in the Department of Justice and Department of Defense’s coordinated efforts to conduct investigations into alleged violations of the [...]
October 31, 2016 — The U.S. Department of Justice (DOJ) and two U.S. Attorney's offices have officially entered the national discussion on drug pricing and the role of Pharmacy Benefit Managers (PBMs) with the initiation of investigatory proceedings against Express Scripts. In a recent Securities and Exchange Commission filing, Express Scripts disclosed that it has received [...]
